Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P27695 |
APEX1_HUMAN |
Retinopathy [ICD-11: 9B71] |
P27695 |
APEX1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P27695 |
APEX1_HUMAN |
Ocular cancer [ICD-11: 2D00-2D07] |
P27695 |
APEX1_HUMAN |
Brain cancer [ICD-11: 2A00] |
P27695 |
APEX1_HUMAN |
Melanoma [ICD-11: 2C30] |
P25779 |
CYSP_TRYCR |
Parasitic worm infestation [ICD-11: 1F90] |
P25779 |
CYSP_TRYCR |
Malaria [ICD-11: 1F40-1F45] |
P51449 |
RORG_HUMAN |
Autoimmune disease [ICD-11: 4A40-4A45] |
P51449 |
RORG_HUMAN |
Lung cancer [ICD-11: 2C25] |
P51449 |
RORG_HUMAN |
Psoriasis [ICD-11: EA90] |
P51449 |
RORG_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P51449 |
RORG_HUMAN |
Crohn disease [ICD-11: DD70] |
P51449 |
RORG_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P51449 |
RORG_HUMAN |
Arterial occlusive disease [ICD-11: BD40] |
P51449 |
RORG_HUMAN |
Liver cancer [ICD-11: 2C12] |
P51449 |
RORG_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |